4 Stocks if (Gulp) Israel Attacks Iran

Israel may soon attack Iran to inhibit or stop its nuclear capabilities. The compassionate person recoils at an investment discussion now, but the steely and rational investor safeguards the financial future for loved ones. Man or woman up. Do what needs to be done.

No one knows what lies behind doors No. 1, 2, or 3, but here's how to prepare for the short-, medium-, and long-term probabilities of an attack and its aftermath. In every case, fear will rule and market volatility will go nuts. The main rule is to own or buy with a margin of safety for the uncertain future. That way, you're good if we have the best of all possible worlds, but also protected in at least some of your stocks for the paper losses others will face.

One stock no matter what
There is one stock for any scenario that is deeply underpriced relative to intrinsic value. Military and commercial contractor L-3 Communications (NYS: LLL) sells at about a 50% discount to intrinsic value and recently upped its dividend yield to close to 3%. You don't have to predict the future or its effect on military spending when you have these odds of reward to risk. It's a bird in the hand and one in the bush.

Short term: Oil
Off the bat, the fear will be that Iran will close the Strait of Hormuz, passageway for 20% of the world's oil and 35% of that which moves by sea. Oil prices will explode upward -- emotion will rule before any careful examination of supply and demand. That will raise fears of recessions among oil importers. In short, the stock market will plummet broadly -- except for oil producers.

Whatever you think of oil prices today and the prospects of stocks you may own, today you can buy oil companies that offer a margin of safety should oil prices decline -- no attack, war, recessions, or deflation (how's that for a list?) -- and upside if oil supplies are threatened and prices rise.

Among the majors, the best-priced today is ConocoPhillips (NYS: COP) . It's rising near its precrash high, including dividends, but it's a better deal now. It not only offers a 3.4% dividend yield but also the special situation catalyst of a $5 billion current stock buyback with potential for another $5 billion repurchase in the second half of the year. These opportunistic repurchases could amount to a whopping 10% of its current market cap. Plus, after selling about $20 billion of assets already, the company plans up to another $10 billion this year. That includes the special situation of the planned Phillips 66 refining spinoff on May 1.

Evolution Petroleum (ASE: EPM) is relatively unknown but offers multiple catalysts for a potential rise. It's a good investment today and protection against oil shocks ahead. Unknown to almost everyone, this small-cap U.S. producer obtains close to Brent prices for its oil -- prices that are around a $16 to $17 per-barrel premium to West Texas Intermediate today. Evolution shares at $9 sell at a discount both to my current intrinsic value estimate of $13 and the potential for even greater value, but be careful not to pay much over today's price of the low $9s to obtain the best reward-to-risk odds. It's a good buy but not a screaming one. (I own shares.)

Medium term: Retaliation
Currently, both sides are fighting a war covertly, almost certainly picking off important players here and there through black ops. A military response would be next. To retaliate by bombing Jerusalem appears impossible because it would destroy a historic, sacred place to the Palestinians, and Iran would lose some support. Tel Aviv? Israeli ports? It's horrible and impossible to figure. But also remember that Israel would be -- certainly is -- prepared. It won't be napping. Nevertheless, broad worldwide market sell-offs would be inevitable. This would include stocks of publicly held companies with large operations in Israel. (Again, this is rationality, not politics talking.)

Cue Austin Powers: "Or would it?" It's impossible that an Israeli-based company of any size lacks a back-up plan for war, including both foreign facilities and double-secret-redundant data facilities in cloud servers around the world. That doesn't mean their stocks wouldn't be hurt -- perhaps for years. But the long-term business operations would likely continue. It may be time (c'mon, Tom, man up!) to buy them.

Shares of tip-top generic-drug producer Teva Pharmaceutical (NAS: TEVA) , also building a proprietary drug business, would almost certainly drop, but its worldwide manufacturing and R&D facilities would mean the contagion would not be fatal. It would be an attractive long-term buy.

Longer term: War and U.S. entry
Listening to the administration's pronouncements, the U.S. has almost no choice but to get involved if there's a war involving Israel. If this happens, the U.S. would have to once again up its military budget, though to what extent would be impossible to predict. This would lead to the kind of decisions made in the Iraq and Afghanistan wars -- more budget deficits without compensating cuts. The only possible solution this time will be inflation.

I repeat: All the debates about inflation will be off the table. There is no room left. Money will be printed and spent. Velocity -- the moving around of money that gives it a multiplier effect and is the sine qua non of inflation -- will no longer be held back, as today, but will increase.

Sure, in the shorter term, money would flow to U.S. Treasuries in a torrent that would make recent years look like a trickle from a leaky faucet and borrowing rates might actually fall -- is this possible where they are almost all negative in real terms? -- and keep government deficit funding cheap. But the odds of higher inflation would greatly increase, where today low monetary velocity has kept it from exploding.

Let's hope not one of these events comes to pass and that diplomacy is the victor. But also, let's carry water in the trunk -- these three and potentially four stocks -- for being stranded on a highway in Death Valley and hope we don't have to use it.

At the time thisarticle was published Tom Jacobsis lead advisor for Motley Fool Special Ops, a special situations and opportunistic value service.You canemailhim and follow him on Twitter @TomJacobsInvest.He owns shares of Evolution Petroleum, but he holds no other position in any company mentioned.Click hereto see his holdings and a short bio. The Motley Fool owns shares of Teva Pharmaceutical, L-3 Communications, and Evolution Petroleum.Motley Fool newsletter serviceshave recommended buying shares of Teva Pharmaceutical and L-3 Communications. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.